February 15, 2017
Adocia’s revenue for 2016 down 40% year over year, develops Lispro on its own after Lilly’s deal break-up
Adocia plans to license its diabetes treatment products, especially its most advanced program BioChaperone Lispro. The company’s boss said that cash position of €58 million will enable the company to push BioChaperone Lispro into phase 3 clinical trial.
